BCMA CAR-T Cells (Pregene)

靶向BCMA的嵌合抗原受体T细胞 （普瑞金）

Report date: 2024/10/09 11:18:06

Base Information

Drug NameBCMA CAR-T Cells (Pregene)
Drug Alias NameBCMA nanobody CAR-T cells (Pregene)CART-BCMA (Pregene)BCMA nano-antibody CAR-T cell therapy (Pregene)BCMA-targeted chimeric antigen receptor T cells (Pregene)B-cell maturation antigen CAR-T cell therapy (Pregene) +[10] 
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-BCMA
TargetsB-cell maturation protein
Therapy Area/IndicationsImmunoglobulin G4-Related DiseasePurpura, Thrombocytopenic, IdiopathicLupus Nephritis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShenzhen Pregene Biopharma Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesCellPoint BVGalapagos NvDr.Reddy's Laboratories Ltd +[6] 
Inactive CompaniesN/A
Active IndicationsImmunoglobulin G4-Related DiseasePurpura, Thrombocytopenic, IdiopathicLupus Nephritis +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A